Sun Pharmaceutical Industries' landmark $11.75 billion acquisition of US-based Organon & Co is set to strategically expand its portfolio into high-growth women's health and biosimilars segments, despite potential integration complexities and debt considerations.
Key Points
- Sun Pharmaceutical Industries acquired US-based Organon & Co. for $11.75 billion, marking India's largest overseas pharma acquisition.
- The deal provides Sun Pharma entry into women's health and biosimilars, segments with lower competition and high growth potential.
- Brokerages maintain 'buy' ratings, citing reasonable valuations and potential for cross-selling and cost savings of over $350 million.
- Key challenges include Organon's $8.5 billion debt, a potential slowdown in the combined entity's growth rate, and the complexity of integrating a company of comparable revenue size.
- Meaningful gains from synergies are not expected until 2028-29 due to the scale and complexity of the integration.
The stock of the country’s largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries, rose 7 per cent on Monday after the company announced the acquisition of US-based pharma major Organon & Co.
It was the top gainer on both the Sensex and the Nifty 50.
At an enterprise value of $11.75 billion, the deal is the largest overseas acquisition by an Indian pharma company.
The sharp gains in the stock largely stem from a lower-than-expected acquisition price compared with initial enterprise value expectations of $13 billion.
Strategic Expansion and Valuation Insights
The valuation, at 6.2x enterprise value to operating profit (EV/Ebit) on a trailing 12-month basis, is lower than that of similar-sized listed entities in the US specialty segment, which trade at around 7-8x.
Near-term triggers for the stock include Organon’s first quarter (January-March/Q1) results on May 7 (and commentary on its growth outlook) and Sun’s consolidated financials for the fourth quarter (January-March/Q4).
Most brokerages continue to maintain a “buy” rating on the company following the acquisition.
The acquisition of a business spun off from Merck in 2021 offers Sun entry into women’s health and biosimilars — two areas where it currently has no exposure.
According to analysts led by Bino Pathiparampil of Elara Securities, these segments face lower competition in fast-growing markets compared with the regular generics business in regulated markets.
The deal improves the Indian market leader’s penetration into select large markets such as China and South Korea.
The analysts expect Sun to enhance operating efficiency and derive further value from the acquisition.
The brokerage has a “buy” rating on the stock with a target price of Rs 1,968.
Synergies and Potential Challenges
In addition to cross-selling opportunities and product development synergies, the acquisition will help expand Sun’s innovative medicines portfolio from 19 per cent to 27 per cent and diversify its specialty basket beyond dermatology and ophthalmology.
Combined synergies could lead to cost savings of over $350 million over the next two to four years.
While there are multiple opportunities and valuations are reasonable, brokerages flag key challenges for the combined entity. Analysts Mehul Sheth and Divyaxa Agnihotri of HDFC Securities believe the growth rate for the combined entity could fall to the mid-single digits, from 10-12 per cent for Sun standalone — posing a major near-term overhang.
While Sun has a strong track record of integrating large acquisitions and turning them value-accretive, challenges remain in integrating another company of comparable revenue size operating in different therapy areas.
Financial Implications and Future Outlook
Further, while Sun is sitting on $3.2 billion in free cash, Organon carries debt of $8.5 billion, which could weigh on earnings, especially if growth slows.
Over the past couple of quarters, Organon has indicated that calendar year 2026 will likely be a flat year. While women’s health and biosimilars are its growth drivers, the laggard among its three segments is Established Brands, which accounts for 55 per cent of revenue.
This segment has been on a declining trend, with its contribution down from 65 per cent earlier.
Whether the two smaller divisions and growth brands can offset this slowdown will determine Organon’s overall growth trajectory.
Given the scale and complexity of integrating Organon into Sun, brokerages believe it could be 2028-29 before the consolidated entity begins to see meaningful gains from synergies.
Commenting on the impact of the acquisition, HDFC Securities expects Sun’s overall sales, operating profit, and bottom line to rise by 80 per cent, 82 per cent, and 27 per cent, respectively.
The relatively lower earnings growth reflects higher interest costs and depreciation.
The brokerage has a “buy” rating on the stock with a target price of Rs 2,030, valuing the company at 31x 2027-28 earnings and implying a multiple of 21x EV/Ebit.
Disclaimer: This article is meant for information purposes only. This article and information do not constitute a distribution, an endorsement, an investment advice, an offer to buy or sell or the solicitation of an offer to buy or sell any securities/schemes or any other financial products/investment products mentioned in this article to influence the opinion or behaviour of the investors/recipients.
Any use of the information/any investment and investment related decisions of the investors/recipients are at their sole discretion and risk. Any advice herein is made on a general basis and does not take into account the specific investment objectives of the specific person or group of persons. Opinions expressed herein are subject to change without notice.
